Atrophic Gastritis Cell Models for Research

Atrophic gastritis is a chronic inflammatory condition of the gastric mucosa, characterized by the loss of gastric glandular cells and their replacement by intestinal-type epithelium (intestinal metaplasia) or fibrous tissue. It is a precursor lesion in the Correa cascade leading to gastric adenocarcinoma. Globally, the prevalence of atrophic gastritis is estimated at 10-20% of the population, with higher rates in East Asia, Eastern Europe, and South America (WHO, 2023). The primary etiological factor is Helicobacter pylori infection, accounting for approximately 60-90% of cases, with autoimmune gastritis as a less common cause (WHO, 2023).

The 5-year survival rate for gastric cancer, the end-stage consequence of atrophic gastritis, is around 32% for all stages combined, but drops to 6% for distant-stage disease (NCI SEER, 2023). Early detection and intervention in atrophic gastritis can prevent progression to cancer, making it a critical target for research. The annual incidence of gastric cancer is over 1 million new cases worldwide, with a mortality rate of approximately 769,000 deaths per year (WHO GLOBOCAN, 2020).

Atrophic gastritis is an ideal model for studying chronic inflammation-driven carcinogenesis, metaplastic transformation, and the stepwise progression from normal mucosa to cancer. The disease is well-characterized histologically and molecularly, with public datasets available from TCGA (Stomach Adenocarcinoma) and GEO (gene expression profiles of gastric metaplasia). Key open questions include the molecular drivers of metaplasia, the role of the gastric microbiome, and the identification of biomarkers for progression risk. Gene-edited cell models enable mechanistic studies of these processes, allowing researchers to dissect the contribution of specific genetic alterations in a controlled environment.

The progression from atrophic gastritis to gastric cancer involves several key pathways:

1. Chronic inflammation and oxidative stress: H. pylori infection induces chronic inflammation, leading to increased production of reactive oxygen species (ROS) and DNA damage.

2. Intestinal metaplasia: Transdifferentiation of gastric epithelial cells to an intestinal phenotype, driven by aberrant expression of transcription factors such as CDX2 and SOX2.

3. Epigenetic silencing: Hypermethylation of tumor suppressor gene promoters (e.g., CDH1, MLH1) leading to loss of function.

4. Genetic mutations: Accumulation of mutations in oncogenes (e.g., KRAS, PIK3CA) and tumor suppressors (e.g., TP53, APC) as the lesion progresses to dysplasia and cancer.

Data from TCGA (Stomach Adenocarcinoma) and COSMIC (v100).

Key signaling networks deregulated in atrophic gastritis and gastric cancer include:

• • Wnt/beta-catenin pathway: Activation via mutations in CTNNB1 or loss of APC, leading to nuclear beta-catenin accumulation and transcriptional activation of target genes (e.g., MYC, CCND1).
• • MAPK/ERK pathway: Constitutive activation through KRAS or BRAF mutations, promoting cell proliferation and survival.
• • PI3K/AKT/mTOR pathway: Activation via PIK3CA mutations or PTEN loss, enhancing cell growth and metabolism.
• • TGF-beta/SMAD pathway: Loss of SMAD4 or TGFBR2 mutations, leading to resistance to growth inhibition and increased invasion.
• • NF-kB pathway: Chronic inflammation activates NF-kB, promoting survival and inflammatory cytokine production.

Gene-edited cell models targeting these pathways are essential for dissecting their roles in disease progression.

Organoids derived from gastric tissue (normal, metaplastic, or cancerous) recapitulate the 3D architecture and cellular heterogeneity of the disease. They can be gene-edited to introduce or correct mutations, providing a more physiologically relevant model than 2D cell lines.

• • Patient-derived xenografts (PDX): Immunodeficient mice engrafted with patient tumor tissue, preserving the genetic and histological features of the original tumor.
• • Genetically engineered mouse models (GEMM): Mice with conditional knockouts or knock-ins of genes such as Tp53, Cdh1, or Kras, mimicking human disease progression.
• • H. pylori-induced models: Mongolian gerbils or mice infected with H. pylori to study the inflammatory response and metaplasia development.
• • Chemical-induced models: Administration of N-methyl-N-nitrosourea (MNU) or N-nitroso compounds to induce gastric carcinogenesis.

These models are valuable for in vivo validation of gene-edited cell line findings.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific genetic alterations, providing a controlled system to study the functional consequences of mutations. Examples include:

• • TP53 knockout in GES-1 or MKN45 cells to model loss of tumor suppressor function.
• • KRAS G12D knock-in in AGS or GES-1 cells to activate the MAPK pathway.
• • CDH1 knockout in MKN45 cells to study epithelial-mesenchymal transition.
• • Reporter lines (e.g., GFP-tagged CDX2) to monitor metaplasia markers.

These gene-edited cell models are commercially available from various sources, sequence-verified, and quality-controlled, accelerating research by eliminating the need for in-house editing. They are essential for functional genomics, drug screening, and biomarker discovery.

Gene-edited cell lines are used to validate the role of specific genes in atrophic gastritis progression. For example:

• • TP53 knockout lines show increased proliferation and resistance to apoptosis, confirming its tumor suppressor role.
• • KRAS G12D knock-in lines exhibit constitutive MAPK activation, leading to enhanced cell growth and invasion.
• • CDH1 knockout lines display loss of cell adhesion and increased migration, supporting its role in diffuse gastric cancer.

These models allow researchers to perform gain-of-function and loss-of-function studies in a controlled genetic background.

Isogenic pairs (e.g., wild-type vs. TP53 knockout) are used in high-throughput drug screens to identify compounds that selectively target mutant cells. This approach can reveal synthetic lethal interactions and resistance mechanisms. For example:

• • Screening for compounds that induce apoptosis in TP53-null cells but not in wild-type cells.
• • Testing the efficacy of MEK inhibitors in KRAS-mutant vs. wild-type lines.
• • Studying acquired resistance to targeted therapies by generating resistant clones from gene-edited lines.

CRISPR-based synthetic lethality screens using gene-edited cell lines can identify novel biomarkers and therapeutic targets. For instance:

• • Genome-wide CRISPR knockout screens in TP53-null cells to find genes essential for survival.
• • Identifying genes that, when knocked out, sensitize cells to chemotherapy or immunotherapy.
• • Discovering secreted proteins from metaplastic cells that serve as non-invasive biomarkers for early detection.